Thesecompanies control 96% of the global insulin supply, and the failure of governmentsto outsource from different manufacturers means medicines get stockout if thesecompanies do not meet demand.28 The WHO prequalificationprogramme, whereby the WHO prequalifies the quality of biosimilarinsulins,29 could help increase access to insulins and other key medicinesby encouraging through increasing competition low-priced diabetes medicines andequipment that meet agreed quality, safety and efficacy standards. The gene discussed is INS; the disease is diabetes mellitus.